Arch Biopartners Valuation
| ARCH Stock | CAD 1.94 0.01 0.51% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. Arch Biopartners shows a prevailing Real Value of C$1.86 per share. The current price of the firm is C$1.94. Our model approximates the value of Arch Biopartners from analyzing the firm fundamentals such as return on asset of -0.81, and Operating Margin of (1.39) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Arch Biopartners' valuation include:
Enterprise Value 131.6 M | Enterprise Value Ebitda (97.59) | Price Sales 91.5233 | Enterprise Value Revenue 53.0545 |
Overvalued
Today
Please note that Arch Biopartners' price fluctuation is risky at this time. Calculation of the real value of Arch Biopartners is based on 3 months time horizon. Increasing Arch Biopartners' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Arch stock is determined by what a typical buyer is willing to pay for full or partial control of Arch Biopartners. Since Arch Biopartners is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Arch Stock. However, Arch Biopartners' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.94 | Real 1.86 | Hype 1.93 | Naive 1.94 |
The intrinsic value of Arch Biopartners' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Arch Biopartners' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Arch Biopartners helps investors to forecast how Arch stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Arch Biopartners more accurately as focusing exclusively on Arch Biopartners' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Arch Biopartners' intrinsic value based on its ongoing forecasts of Arch Biopartners' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Arch Biopartners' closest peers.
Arch Biopartners Cash |
|
Arch Valuation Trend
Analysing the historical paterns of Arch Biopartners' enterprise value and its market capitalization is a good way to estimate and gauge the value of Arch Biopartners over time and is usually enough for investors to make rational market timing decisions.
Arch Biopartners Total Value Analysis
Arch Biopartners is presently forecasted to have takeover price of 131.58 M with market capitalization of 129.88 M, debt of 5.02 M, and cash on hands of 72.82 K. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Arch Biopartners fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
131.58 M | 129.88 M | 5.02 M | 72.82 K |
Arch Biopartners Investor Information
About 20.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.03. Arch Biopartners last dividend was issued on the 13th of September 2000. The entity had 1:3 split on the 25th of November 2003. Based on the key indicators related to Arch Biopartners' liquidity, profitability, solvency, and operating efficiency, Arch Biopartners may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Arch Biopartners Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Arch Biopartners has an asset utilization ratio of 169.37 percent. This indicates that the Company is making C$1.69 for each dollar of assets. An increasing asset utilization means that Arch Biopartners is more efficient with each dollar of assets it utilizes for everyday operations.Arch Biopartners Ownership Allocation
Arch Biopartners holds a total of 64.94 Million outstanding shares. Arch Biopartners shows 19.86 percent of its outstanding shares held by insiders and 0.0 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Arch Biopartners Profitability Analysis
The company reported the revenue of 1.98 M. Net Loss for the year was (3.33 M) with loss before overhead, payroll, taxes, and interest of (502.88 K).About Arch Biopartners Valuation
Our relative valuation model uses a comparative analysis of Arch Biopartners. We calculate exposure to Arch Biopartners's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Arch Biopartners's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -116.1 K | -121.9 K | |
| Pretax Profit Margin | (0.18) | (0.19) | |
| Operating Profit Margin | (0.09) | (0.10) | |
| Net Loss | (0.18) | (0.19) | |
| Gross Profit Margin | 0.20 | 0.21 |
Additional Tools for Arch Stock Analysis
When running Arch Biopartners' price analysis, check to measure Arch Biopartners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arch Biopartners is operating at the current time. Most of Arch Biopartners' value examination focuses on studying past and present price action to predict the probability of Arch Biopartners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arch Biopartners' price. Additionally, you may evaluate how the addition of Arch Biopartners to your portfolios can decrease your overall portfolio volatility.